AstraZeneca Forecast, price target & analysts
AstraZeneca Target price 2024 - Analyst rating & recommendation
AstraZeneca Classifications & Recommendation:
AstraZeneca Price Target
| Target Price | GBP137.65 |
| Price | GBP100.62 |
| Potential | 36.80% |
| Number of Estimates | 25 |
| 25 Analysts have issued a price target AstraZeneca 2025 . The average AstraZeneca target price is GBP137.65. This is 36.80% higher than the current stock price. The highest price target is GBP181.20 80.08% , the lowest is GBP105.70 5.05% . | |
| A rating was issued by 29 analysts: 23 Analysts recommend AstraZeneca to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2025 of 36.80% . Most analysts recommend the AstraZeneca stock at Purchase. |
Sales and Margin forecast 2024, 2025 to 2028
25 Analysts have issued a sales forecast AstraZeneca 2024 . The average AstraZeneca sales estimate is GBP41.9b . This is 3.86% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP42.8b 6.11% , the lowest is GBP39.7b 1.65% .
This results in the following potential growth metrics:
Revenue Estimates
| 2023 | GBP36.9b | 2.36% |
|---|---|---|
| 2024 | GBP41.9b | 13.79% |
| 2025 | GBP45.2b | 7.85% |
| 2026 | GBP48.0b | 6.18% |
| 2027 | GBP51.0b | 6.18% |
| 2028 | GBP53.6b | 5.13% |
17 Analysts have issued an AstraZeneca EBITDA forecast 2024. The average AstraZeneca EBITDA estimate is GBP14.2b . This is 13.86% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP17.4b 39.49% , the lowest is GBP12.0b 3.58% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2023 | GBP11.5b | 37.82% |
|---|---|---|
| 2024 | GBP14.2b | 22.94% |
| 2025 | GBP16.0b | 13.03% |
| 2026 | GBP17.6b | 9.83% |
| 2027 | GBP19.2b | 9.27% |
| 2028 | GBP19.5b | 1.57% |
EBITDA Margin
| 2023 | 31.31% | 34.65% |
|---|---|---|
| 2024 | 33.83% | 8.04% |
| 2025 | 35.45% | 4.79% |
| 2026 | 36.67% | 3.44% |
| 2027 | 37.74% | 2.92% |
| 2028 | 36.46% | 3.39% |
16 AstraZeneca Analysts have issued a net profit forecast 2024. The average AstraZeneca net profit estimate is GBP6.7b . This is 30.31% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP7.6b 47.94% , the lowest is GBP5.6b 10.18% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2023 | GBP4.8b | 79.65% |
|---|---|---|
| 2024 | GBP6.7b | 39.16% |
| 2025 | GBP8.3b | 25.20% |
| 2026 | GBP9.6b | 15.33% |
| 2027 | GBP11.4b | 18.59% |
| 2028 | GBP13.2b | 15.20% |
Net Margin
| 2023 | 13.00% | 75.52% |
|---|---|---|
| 2024 | 15.90% | 22.32% |
| 2025 | 18.45% | 16.04% |
| 2026 | 20.04% | 8.62% |
| 2027 | 22.39% | 11.73% |
| 2028 | 24.53% | 9.56% |
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
16 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is GBP4.30 . This is 30.30% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is GBP4.88 47.88% , the lowest is GBP3.64 10.30% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2023 | GBP3.09 | 79.65% |
|---|---|---|
| 2024 | GBP4.30 | 39.16% |
| 2025 | GBP5.38 | 25.12% |
| 2026 | GBP6.21 | 15.43% |
| 2027 | GBP7.36 | 18.52% |
| 2028 | GBP8.48 | 15.22% |
P/E ratio
| Current | 30.18 | 9.04% |
|---|---|---|
| 2024 | 23.18 | 23.19% |
| 2025 | 18.52 | 20.10% |
| 2026 | 16.06 | 13.28% |
| 2027 | 13.54 | 15.69% |
| 2028 | 11.75 | 13.22% |
Based on analysts' sales estimates for 2024, the AstraZeneca stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.16 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.69 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.32 | 11.11% |
|---|---|---|
| 2024 | 4.16 | 3.70% |
| 2025 | 3.86 | 7.28% |
| 2026 | 3.63 | 5.82% |
| 2027 | 3.42 | 5.82% |
| 2028 | 3.25 | 4.88% |
P/S ratio
| Current | 3.83 | 11.65% |
|---|---|---|
| 2024 | 3.69 | 3.71% |
| 2025 | 3.42 | 7.28% |
| 2026 | 3.22 | 5.82% |
| 2027 | 3.03 | 5.82% |
| 2028 | 2.88 | 4.88% |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
